Xiamen Tebao a new drug pegylated interferon α - 2b injection officially declared for production

According to the website of the State Food and Drug Administration (CFDA), Tonghua Dongbao joint stock company Xiamen Tebao Bioengineering Co., Ltd has officially applied for the production of polyethylene glycol interferon α - 2b injection, which is a national first-class new drug The approved production will break the monopoly of foreign enterprises Pegylated interferon α - 2b injection was used to treat chronic hepatitis B and C Among the similar products in the world, only Schering plough's recombinant human interferon α - 2b (trade name "Intron-A", ganleneng, listed in 1991) and Roche's long-acting interferon polyglycosylated α - 2A (trade name "Pegasys", listed in 2005) jointly occupy more than half of the hospital's anti hepatitis B interferon market Previously, Xiamen terbo long-acting interferon in the treatment of chronic hepatitis C phase III clinical trial in the middle results showed that the treatment of chronic hepatitis C patients with a high virus response rate About 45 million people live with hepatitis C virus in China, and 120 million people live with hepatitis B virus The project is a national major clinical research project for new drug creation during the 12th Five Year Plan period Xiamen Tebo has obtained patent authorization from nearly 30 countries, including the United States, Europe, Japan, Australia and China However, an investor who has long paid close attention to Tonghua Dongbao is not optimistic about the profits brought by the drug to the company He analyzed that it is possible to be listed and sold in 2018, and Xiamen Tebao will increase its capital and share before IPO, when Dongbao's equity may be diluted, not only that, but also there are adverse reactions such as nausea and swelling of face in the clinical patients Amoytop Bioengineering Co., Ltd., founded in 1994, is a high-tech enterprise specializing in the research and development of genetic engineering technology and the industrialization of biomedicine, integrating research, development, production and sales.